135 related articles for article (PubMed ID: 30593980)
1. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
Arreola-Mora C; Silva-Pereyra J; Fernández T; Paredes-Cruz M; Bertado-Cortés B; Grijalva I
Mult Scler Relat Disord; 2019 Feb; 28():117-124. PubMed ID: 30593980
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
5. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
6. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
[TBL] [Abstract][Full Text] [Related]
7. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.
Rossini PM; Pasqualetti P; Pozzilli C; Grasso MG; Millefiorini E; Graceffa A; Carlesimo GA; Zibellini G; Caltagirone C
Mult Scler; 2001 Dec; 7(6):354-8. PubMed ID: 11795455
[TBL] [Abstract][Full Text] [Related]
8. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
Foschi M; Lugaresi A
Expert Opin Pharmacother; 2019 Aug; 20(11):1309-1320. PubMed ID: 31237780
[No Abstract] [Full Text] [Related]
9. [Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis].
Cabrera-Gómez JA; Echazábal-Santana N; Porrero-Martín P; Valenzuela-Silva C; Rodríguez CA; Fuentes-Suárez I; Pérez-Ruiz L; Ramos-Cedeño AM; Cabrera-Núñez JA;
Rev Neurol; 2003 Aug 1-15; 37(3):214-20. PubMed ID: 12938052
[TBL] [Abstract][Full Text] [Related]
10. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Pavsic K; Pelicon K; Ledinek AH; Sega S
Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
[TBL] [Abstract][Full Text] [Related]
11. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
12. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
van Diemen HA; Polman CH; van Dongen TM; van Loenen AC; Nauta JJ; Taphoorn MJ; van Walbeek HK; Koetsier JC
Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
Kappos L; Arnold DL; Bar-Or A; Camm J; Derfuss T; Kieseier BC; Sprenger T; Greenough K; Ni P; Harada T
Lancet Neurol; 2016 Oct; 15(11):1148-59. PubMed ID: 27543447
[TBL] [Abstract][Full Text] [Related]
14. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
Morrow SA; Rosehart H; Johnson AM
Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
[TBL] [Abstract][Full Text] [Related]
17. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis.
Mattioli F; Stampatori C; Zanotti D; Parrinello G; Capra R
J Neurol Sci; 2010 Jan; 288(1-2):101-5. PubMed ID: 19825502
[TBL] [Abstract][Full Text] [Related]
19. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
20. Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study.
Bruce J; Hancock L; Roberg B; Brown A; Henkelman E; Lynch S
Cogn Behav Neurol; 2012 Sep; 25(3):107-14. PubMed ID: 22960434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
